Today's Research Daily features new research reports on 16 major stocks, including Mastercard Incorporated (MA), The Procter ...

Pfizer, facing increasing pressure from Novartis, is touting a Phase III win for Ibrance as the first clinical evidence supporting the CDK4/6 inhibitor class’ use in patients with a specific type of ...

While under competitive pressure from Novartis and Eli Lilly, Pfizer can tally up a unique trial win for its Ibrance in a ...

Although not a game changer for Pfizer, the data could help cushion Ibrance’s losses of market share to Kisqali, a similar ...

Among patients with ER-positive/HER2-negative advanced breast cancer, treatment with camizestrant in combination with Kisqali ...

It looks like Eli Lilly’s oral selective estrogen receptor degrader (SERD) imlunestrant may need some extra help to reach a ...

Experts discussed what other information is needed to understand how best to use Kisqali in treating patients in the adjuvant ...

Zealand Pharma announces that the first participant has been enrolled in the Phase 2b ZUPREME-1 trial of petrelintide in ...

Novartis (NVS) announced results from an updated analysis of the pivotal Phase 3 NATALEE trial of Kisqali that it says “underscore the extended ...

Reduction in distant recurrence consistently deepened beyond 3-year Kisqali treatment duration in patients with node-positive (N+) and high-risk node-negative (N0) disease, as well as between ...

Olema presented Phase 1b/2 trial data for palazestrant combined with Novartis's Kisqali in ER-positive, HER2-negative breast ...